[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607906":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":22,"centralContacts":23,"locations":22,"responsibleParty":33,"collaborators":22,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":22,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":44,"maxAge":22,"enrollmentInfo":45,"targetDuration":22,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":22,"overallStatus":54,"whyStopped":22,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":22},{"fullName":5,"class":6},"University of Nebraska","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Unblinded CGM","Nursing staff will compare CGM and POC-BG readings every 1 to 2 hours using institutional blood glucose meters. Validated CII calculator will be utilized. Validation will be considered successful when two consecutive CGM readings were within 20% of the POC-BG when BG exceeded 100 mg\u002FdL, or within 20 mg\u002FdL if the POC-BG was below 100 mg\u002FdL. The electronic health records (EHR) will utilize the CGM glucose value entered in the patient flowsheet row for comparison with POC-BG results using the published algorithm above to calculate, confirm, and record the success of the validation.\n\n\\- Ongoing validation phase for the sustained use of CGM. After the initial CGM validation, POC-BG checks and the CGM validation will be reduced to every 6 hours, and CII titration in the interim was guided by CGM values until the next POC-BG assessment.",[12],"Other: Dexcom G7 CGM",{"label":14,"type":6,"description":15,"interventionNames":16},"Blinded CGM","After CGMs are placed (on the abdomen in all participants) and have completed their warm-up period, the nursing staff will proceed with standard of care POC finger sticks. The blinded CGM data will not be visible to the participant, nursing staff, or other care providers. The blinded CGM data will be used for data analysis following the completion of the participant's participation.",[12],[18],{"type":6,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"Dexcom G7 CGM","The Dexcom G7 is a continuous glucose monitor, FDA 510K cleared (K213919) for people with diabetes. Worn for 10 days at a time, the device monitors the glucose levels of interstitial fluid and, via bluetooth, transmits data every 5 minutes to a receiver.",[14,9],null,[24,29],{"name":25,"role":26,"phone":27,"phoneExt":22,"email":28},"Andjela Drincic, MD","CONTACT","4025596276","andjela.drincic@unmc.edu",{"name":30,"role":26,"phone":31,"phoneExt":22,"email":32},"Aditya Chandlekar, MS","4025597083","achandlekar@unmc.edu",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Andjela Drincic","Professor","100607906","feasibility-and-performance-of-continuous-glucose-monitoring-to-guide-computerized-insulin-infusion-therapy-in-non-icu-patients-receiving-corticosteroid-therapy-and-specialized-nutrition-100607906",false,"NCT07194642","Feasibility and Performance of Continuous Glucose Monitoring to Guide Computerized Insulin Infusion Therapy in Non-ICU Patients Receiving Corticosteroid Therapy and Specialized Nutrition","Inclusion Criteria:\n\n* Age \\>19 years old\n* Patients with diabetes or stress induced hyperglycemia requiring continuous insulin infusion therapy, with anticipated duration of this therapy being \\> 24 hours. Specifically, we will include\n* Patients with Type 2 diabetes; or if not previously diagnosed as having diabetes, HbA1c \\>7.0% (laboratory-measured at or since hospital admission or within prior 3-months).\n* Type 1 diabetes, as well as atypical forms of diabetes (including pancreatectomy and pancreatitis) and\n* Stress hyperglycemia defined as at least 1 blood glucose measurement \\>180 mg\u002FdL since admission in a patient without history of diabetes, if CII is indicated per treating physician\n* Insulin drip (CII) already initiated since admission or planned to be initiated\n* Non-critical hospitalization with expected duration of CII \\> 24 hours at time of randomization\n* Oncology and post-transplant population receiving IV insulin therapy\n\nExclusion Criteria:\n\n* Inability to provide written consent\n* Medically unstable patients receiving pressor therapy and ICU level of care.\n* Patients transferred from ICU with an expected requirement for CII \\> 24 hours on a non-ICU floor are eligible)\n* For women of childbearing potential: currently pregnant or breastfeeding\n* Hypoxia (O2 saturation \\\u003C 90 %) present at time of potential enrollment\n* Hemoglobin \\\u003C 7 mg\u002FdL;\n* Anasarca present at time of potential enrollment\n* Use of hydroxyurea or high dose acetaminophen use of \\>4g daily as those are substances known to interfere with CGM system.\n* eGFR \\\u003C 20 mL\u002Fmin or dialysis being received or planned\n* Known allergy to medical grade adhesives or a skin condition that may impact CGM performance per investigator discretion\n* Admission for Diabetic ketoacidosis or hyperosmolar hyperglycemic state\n\nNurse Participants:\n\n* Adults aged 19 and older involved in the routine care of the patient participants\n* Adequate proficiency to understand and provide informed consent in English","ALL","19 Years",{"count":46,"type":47},80,"ESTIMATED","INTERVENTIONAL",[50],"NA","The objective of this pilot study is to assess the feasibility and performance of real-time CGM for titrating CII via: (1) evaluation of CGM glucose accuracy in oncology and post-transplant population receiving IV insulin therapy, and (2) assessing both nursing acceptance\u002Fconvenience and patient satisfaction with CGM use. A randomized prospective trial model will be used comparing glucose control (glucometrics hypoglycemia), patient experience and nursing satisfaction in cancer patients receiving IV insulin therapy where monitoring is done via: a) hybrid protocol originally developed by Faulds et al. integrating CGM with periodic POC-BG tests to monitor and ensure the ongoing accuracy of CGM measurements (available at http:\u002F\u002Fwww.covidindiabetes.org). b) standard care with hourly POC testing and blinded professional CGM.Inclusion criteria: Eligible patients include oncology and post-transplant patients receiving IV insulin therapy while on corticosteroid treatment and receiving specialized nutrition. Exclusion criteria: medically instable patients receiving pressor therapy and ICU level of care. Outcome evaluation; Patients' characteristics were collected through the EHR. Glucometrics will be collected throughout the study to include mean BS, % in range ( 80-180) , patient day hypoglycemia , patient stay hypoglycemia . Nursing surveys: Survey will be provided for nurses to assess nursing burden, acceptability. Nurses will complete a survey before starting the project and again after being involved in the initial and ongoing validation phases of CGM at the end of the project. The purpose is to report their convenience with using CGM and their preferred glucose monitoring method, which included POC arterial blood, POC finger sticks, and CGM. Nursing surveys will be administrated electronically to nursing staff and the results will be uploaded automatically. Patient survey: Patients will be approached by the team members to inquire about the willingness to provide feedback. The questionnaire will assess their experiences of care with CGM (options: very good, good, fair, poor), glucose check without pain and disruptions of sleep (yes\u002Fno), and overall confidence of care with CGM process (very confident, quite confident, somewhat confident, little confident). Patient surveys will handed out by the team members, and the results were subsequently entered into database (See both nursing and patient surveys in Supplementary Material.)",[53],"Diabetes","NOT_YET_RECRUITING","2026-05-18",{"date":57,"type":58},"2026-05-20","ACTUAL",{"date":60,"type":47},"2026-05-30",{"date":62,"type":47},"2026-11-30",{"name":5,"class":6}]